74 research outputs found
Targeted therapy for advanced gastric cancer: A review of current status and future prospects
No full textIn the West in particular, the vast majority of gastric cancer (GC) patients present with advanced-stage disease. Although combination chemotherapy is still the most important component of treatment for these patients, it confers a modest survival advantage. Recently, increased knowledge of the key molecular signaling pathways involved in gastric carcinogenesis has led to the discovery of specific molecular-targeted therapeutic agents. Some of these agents such as trastuzumab and ramucirumab have changed the treatment paradigm for this disease. In this paper, we will summarize the current clinical status of targeted drug therapy in the management of GC
Demographic, clinical, and outcomes characteristics associated with screening colonoscopy in colorectal cancer patients.
No full text 554 Background: Screening colonoscopy has well established role in CRC prevention. Factors associated with underutilization of screening colonoscopy, and how underutilization affects the CRC outcomes is unclear. We conducted a retrospective study with an aim to identify demographic, clinical and outcome characteristics associated with screening colonoscopy in patients with CRC. Methods: The Indiana Network for Patient Care (INPC) was used to identify patients diagnosed with CRC between 2001-2015. The INPC is the largest and longest tenured clinical data warehouse of the Indiana Health Information Exchange in the USA. Patient demographic (age, race, gender, median household income, insurance type, geographical location), clinical (BMI, year of diagnosis, stage, tumor location, CEA, surgery, chemotherapy, comorbidity) and outcome characteristics were obtained. Only patients who had colonoscopy prior to diagnosis were included, and divided those who received screening colonoscopy versus diagnostic colonoscopy. Chi-square was used for univariate analysis. Multivariate logistic regression was used to model the association of colonoscopy with overall mortality, and CRC-specific mortality. Results: A total of 1546 patients were identified, of which 361 (23.3%) and 1185 (76.6%) had screening and diagnostic colonoscopy, respectively. On univariate analyses, older age, female gender, Caucasian race, lower BMI and lack of insurance, were significantly associated with screening colonoscopy (P < 0.05). Additionally, patients receiving screening colonoscopy had higher likelihood to undergo surgery and receive chemotherapy (P < 0.05). Multivariate analyses adjusted for age, gender, race, surgery, chemotherapy and insurance status showed that screening colonoscopy (as compared with diagnostic colonoscopy) is associated with a 38% lower odds of overall mortality (adjusted OR = 0.62, 95% CI, 0.46-0.83, p < 0.001), and 68% lower odds of CRC-specific mortality (adjusted OR = 0.32, 95% CI, 0.19-0.51, p < 0.001). Conclusions: Screening colonoscopy is associated with decreased odds of overall and CRC-specific mortality and individuals with older age are more likely to receive it. </jats:p
Abstract B167: APX3330 drug development for clinical trials targeting APE1/Ref-1 in pancreatic cancer
No full textImpact of nab-paclitaxel-based second-line chemotherapy on the outcomes of pancreatic cancer.
No full text 483 Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with no standard second line chemotherapies. We conducted a retrospective study with the primary aim to examine the effect of second line chemotherapy with nab-paclitaxel-based regimen on the overall survival (OS) and progression-free survival (PFS) of locally advanced and metastatic PDAC patients. Methods: Indiana University Simon Cancer Center (IUSCC) Cancer Registry was used to identify patients with locally advanced or metastatic PDAC between 2009 and 2015. Only patients who received second line chemotherapies were included in the study. These patients were divided in to two groups: a) nab-paclitaxel-based treatment and, b) non-nab-paclitaxel-based treatment. Demographic (age, race, gender, year of diagnosis, family history, comorbidity), clinical (histology, CA 19-9, bilirubin, tumor location, performance status, metastatic sites, chemotherapy, surgery or radiation) and outcome (OS, PFS) characteristics were obtained. OS and PFS were estimate by using Kaplan-Meier method and 95% CI. Cox proportional-hazard model was used for multivariate analysis. Results: Forty-seven (39%) and seventy-three (61%) patients received nab-paclitaxel-based and non-nab-paclitaxel-based second line chemotherapy, respectively. In the univariate analyses, nab-paclitaxel-based treatment was only associated with younger age (60.4 vs. 64 years; P = 0.02). The median PFS was 2.8 and 2.1 months (HR 0.62; 95% CI 0.38-1.02; P = 0.06), and the median OS was 7.5 and 4.7 months (HR 0.67; 95% CI 0.45-1.00; P = 0.05) in patients who received nab-paclitaxel based second line treatment versus not, respectively. Multivariate analyses adjusted for age showed a significantly improved PFS (adjusted HR 0.60, 95% CI 0.36-0.98; P = 0.04) and a suggestion of improved OS (adjusted HR 0.67; 95% CI 0.44-1.01, P = 0.05) in the nab-paclitaxel based second line treatment group versus not, respectively. Conclusions: In a single institution retrospective study, we report significant improvement in the PFS and a suggestion of improvement in the OS with nab-paclitaxel based treatment as compared with non-nab-paclitaxel based treatment in the second line setting. </jats:p
Abstract 4824: Pancreatic adenocarcinoma: Comparative analysis of cancer stem cell markers between neoadjuvant and treatment naïve specimens
No full text
- …
